ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…
- « Previous Page
- 1
- …
- 12
- 13
- 14